TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37129110

Group type: EXPERIMENTAL
Intervention: Recast therapy embedded in a first-grade science curriculum
Number of subjects: 33

Group type: COMPARATOR
Intervention: Active control (vocabulary + science)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Active control (phonological awareness + science)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Recast therapy
Number of subjects: 33
Study: 37129153

Group type: EXPERIMENTAL
Intervention: RAM+PAC (ramucirumab and paclitaxel)
Number of subjects: 665

Group type: COMPARATOR
Intervention: PL+PAC (placebo and paclitaxel)
Number of subjects: 665
Study: 37129155

Group type: EXPERIMENTAL
Intervention: Capecitabine maintenance after XELOX chemotherapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Observation after XELOX chemotherapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Capecitabine maintenance
Number of subjects: 63
Study: 37129197

Group type: EXPERIMENTAL
Intervention: Selinexor in combination with pembrolizumab
Number of subjects: 17
Study: 37129384

Group type: EXPERIMENTAL
Intervention: MLC901 (NeuroAiD II)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 37129455

Group type: EXPERIMENTAL
Intervention: LCL161 plus oral topotecan
Number of subjects: 35
Study: 37129475

Group type: EXPERIMENTAL
Intervention: Interpersonal racism
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Vicarious racism
Number of subjects: 542
Study: 37129493

Group type: EXPERIMENTAL
Intervention: PI-RADS version 2.1
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: MRI features including three-dimensional diameter, relative lesion volume, sphericity, and surface to volume ratio (SVR)
Number of subjects: 454
Study: 37129584

Group type: EXPERIMENTAL
Intervention: Ropeginterferon α-2b, starting dose of 250 μg, increasing to 350 μg at week 2 and 500 μg at week 4, with adjustments based on tolerability.
Number of subjects: 0
Study: 37129687

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 107
Study: 37129691

Group type: EXPERIMENTAL
Intervention: Digital healthcare rehabilitation group (DR group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional rehabilitation group (CR group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups (DR and CR)
Number of subjects: 56
Study: 37129892

Group type: EXPERIMENTAL
Intervention: QPS (Question Prompt Sheet)
Number of subjects: 130

Group type: COMPARATOR
Intervention: GIS (General Information Sheet)
Number of subjects: 130
Study: 37130017

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 35 cycles (∼2 years)
Number of subjects: 53
Study: 37130044

Group type: EXPERIMENTAL
Intervention: Riluzole treatment for 2 weeks at the dose level approved for ALS
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Riluzole treatment
Number of subjects: 32
Study: 37130076

Group type: EXPERIMENTAL
Intervention: 12-week pelvic floor muscle training (PFMT) program including instruction to perform the knack
Number of subjects: 69
Study: 37130111

Group type: EXPERIMENTAL
Intervention: Sleep-related breathing disorders (SRBDs) severity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) therapy for moderate-to-severe SRBDs
Number of subjects: 0
Study: 37130158

Group type: EXPERIMENTAL
Intervention: Living donor liver transplantation (LDLT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Resection
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (continued systemic chemotherapy)
Number of subjects: 81
Study: 37130297

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37130314

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37130329

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery for gastrointestinal cancer treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37130337

Group type: EXPERIMENTAL
Intervention: PARTNER-MH intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 50
Study: 37130608

Group type: EXPERIMENTAL
Intervention: EPIQ collaborative quality improvement strategies including respiratory and nutritional care bundles, quality improvement team building, education, mentoring, and networking.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control arm with current practices in the first year (all NICUs).
Number of subjects: 12
Study: 37130657

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: NICE guidelines-directed care
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) measures
Number of subjects: 1202
Study: 37130658

Group type: EXPERIMENTAL
Intervention: Systematic coronary physiology (FFR)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA) alone
Number of subjects: 150
Study: 37130668

Group type: EXPERIMENTAL
Intervention: Personalised nutrition plan developed and delivered by a culturally congruent dietitian and health coach; FitBit to track steps
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual care, plus weekly text messages to encourage walking and paper handouts
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Personalised nutrition plan
Number of subjects: 190
Study: 37130670

Group type: EXPERIMENTAL
Intervention: HPI combined with diagnostic guidance protocol
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 130
Study: 37130682

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no FMT)
Number of subjects: 120
Study: 37130681

Group type: EXPERIMENTAL
Intervention: Family support (measured through structure and function variables)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: T2DM remission defined as glycated haemoglobin (HbA1c) <6.0% without medications
Number of subjects: 359
Study: 37130685

Group type: EXPERIMENTAL
Intervention: Rapid serological test (RST) for SARS-CoV-2 antibodies (OrientGene)
Number of subjects: 1073
Study: 37130827

Group type: EXPERIMENTAL
Intervention: Occupational Sedentary Behavior
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Nonoccupational Sedentary Behavior
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: All-domain Sedentary Behavior
Number of subjects: 273
Study: 37131014

Group type: EXPERIMENTAL
Intervention: Metformin + AC-T
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (AC-T only)
Number of subjects: 70
Study: 37131096

Group type: EXPERIMENTAL
Intervention: Machine-learning models using single or serial concentrations of six different hs-cTn assays (ARTEMIS model)
Number of subjects: 2575

Group type: EXPERIMENTAL
Intervention: Single hs-cTn measurement using the ARTEMIS model
Number of subjects: 2575

Group type: EXPERIMENTAL
Intervention: Machine-learning models (ARTEMIS)
Number of subjects: 2575
Study: 37131125

Group type: EXPERIMENTAL
Intervention: Kidney BEAM intervention
Number of subjects: 304

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 304
Study: 37131126

Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 57

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 57
Study: 37131154

Group type: EXPERIMENTAL
Intervention: Standard immunotherapy (IO) regimen administered every 3 months
Number of subjects: 646

Group type: COMPARATOR
Intervention: Reduced intensity dose of IO administered every 3 months
Number of subjects: 646

Group type: COMPARATOR
Intervention: Standard IO regimen
Number of subjects: 646
Study: 37131180

Group type: EXPERIMENTAL
Intervention: Targeted Muscle Reinnervation (TMR)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Regenerative Peripheral Nerve Interface (RPNI)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Neuroma transposition (active control)
Number of subjects: 110
Study: 37131185

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study: 37131191

Group type: EXPERIMENTAL
Intervention: Bupivacaine dose adjusted by height-based dosing algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Constant bupivacaine dose
Number of subjects: 0
Study: 37131217

Group type: EXPERIMENTAL
Intervention: Mini-Hyper-CVD plus inotuzumab with blinatumomab
Number of subjects: 110

Group type: COMPARATOR
Intervention: Mini-Hyper-CVD plus inotuzumab without blinatumomab
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 110

Group type: COMPARATOR
Intervention: Original inotuzumab schedule
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Modified inotuzumab schedule
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Patients receiving allogeneic SCT
Number of subjects: 110
Study: 37131229

Group type: EXPERIMENTAL
Intervention: Centralized prescreening data collection
Number of subjects: 1029
Study: 37131247

Group type: EXPERIMENTAL
Intervention: 24 sessions of 'Goals in Focus' over the course of 6 months (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 6-month wait-list control group (n = 15)
Number of subjects: 30
Study: 37131265

Group type: EXPERIMENTAL
Intervention: Benralizumab (30 mg subcutaneous doses at 4-week intervals)
Number of subjects: 0
Study: 37131531

Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IDA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham IDA
Number of subjects: 72
Study: 37131583

Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS) - Gamma-knife
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS) - LINAC
Number of subjects: 0
Study: 37131643

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37131659

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) with high antibody levels transfused early (symptom onset within 5 days)
Number of subjects: 179

Group type: COMPARATOR
Intervention: COVID-19 convalescent plasma (CCP) with low antibody levels or control plasma
Number of subjects: 179
Study: 37131689

Group type: EXPERIMENTAL
Intervention: Virtual Family-Centered Rounds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard rounds)
Number of subjects: 0
Study: 37131744

Group type: EXPERIMENTAL
Intervention: SVR III participants (140)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Healthy controls (100)
Number of subjects: 240
Study: 37131755

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention focusing on PrEP use and concomitant stimulant use or condomless anal sex
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention with financial incentives for documented evidence of PrEP clinical evaluation and filling a PrEP prescription
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Switch to a second-stage intervention (MI + CM or CM + MI)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Continue with assessments only
Number of subjects: 70
Study: 37131861

Group type: EXPERIMENTAL
Intervention: PHH-1V booster vaccine
Number of subjects: 782

Group type: COMPARATOR
Intervention: BNT162b2 booster vaccine
Number of subjects: 782

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 782
Study: 37132164

Group type: EXPERIMENTAL
Intervention: RN/CHW-led HCV intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: cbSOC (clinic-based standard of care)
Number of subjects: 10
Study: 37132182

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab combined with ipilimumab
Number of subjects: 0
Study: 37132193

Group type: EXPERIMENTAL
Intervention: Targeted axillary dissection (TAD) alone
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Targeted axillary dissection (TAD)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Clipped node detection
Number of subjects: 353
Study: 37132281

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy with gemcitabine 1000 mg/m² and nab-paclitaxel
Number of subjects: 19
Study: 37132337

Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 344

Group type: COMPARATOR
Intervention: EM-D or EM-P
Number of subjects: 344
Study: 37132535

Group type: EXPERIMENTAL
Intervention: Curative embolization
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Pre-embolization
Number of subjects: 1010
Study: 37133249

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical standard of care (chemotherapy)
Number of subjects: 0
Study: 37133402

Group type: EXPERIMENTAL
Intervention: Operatively treated periprosthetic proximal and distal femoral fractures
Number of subjects: 0
Study: 37133429

Group type: EXPERIMENTAL
Intervention: tiotropium bromide/olodaterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: fluticasone furoate/umeclidinium/vilanterol
Number of subjects: 0
Study: 37133501

Group type: EXPERIMENTAL
Intervention: PRESERFLO™ MicroShunt
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 60
Study: 37133586

Group type: EXPERIMENTAL
Intervention: CD4 count <100 cells per cubic millimeter
Number of subjects: 91

Group type: COMPARATOR
Intervention: CD4 count 101 to 300 cells per cubic millimeter
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Overall risk of death
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Prevalence of cancer
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Response to immunization against Covid-19
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Increased susceptibility to diseases
Number of subjects: 91
Study: 37133584

Group type: EXPERIMENTAL
Intervention: Temporary interruption of adjuvant endocrine therapy to attempt pregnancy
Number of subjects: 516

Group type: COMPARATOR
Intervention: Control cohort (external cohort of women who would have met entry criteria)
Number of subjects: 516
Study: 37133585

Group type: EXPERIMENTAL
Intervention: FTD-TPI plus bevacizumab (combination group)
Number of subjects: 246

Group type: COMPARATOR
Intervention: FTD-TPI alone (FTD-TPI group)
Number of subjects: 246
Study: 37133647

Group type: EXPERIMENTAL
Intervention: Guideline-recommended medications (ACE inhibitors)
Number of subjects: 26851

Group type: EXPERIMENTAL
Intervention: Guideline-recommended medications (Angiotensin receptor blockers)
Number of subjects: 26851

Group type: EXPERIMENTAL
Intervention: Guideline-recommended medications (Mineralocorticoid receptor antagonists)
Number of subjects: 26851

Group type: EXPERIMENTAL
Intervention: CKD diagnosis
Number of subjects: 26851

Group type: EXPERIMENTAL
Intervention: Delay in CKD diagnosis by 1 year
Number of subjects: 26851
Study: 37133673

Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (HDDT): rabeprazole 20 mg and amoxicillin 750 mg q.i.d for 14 days (n=122)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Rabeprazole-containing hybrid therapy (HT): rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days (n=121)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Adverse events in HDDT group
Number of subjects: 243

Group type: COMPARATOR
Intervention: Adverse events in HT group
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Coffee drinking habit in HDDT group
Number of subjects: 243

Group type: COMPARATOR
Intervention: Coffee drinking habit in HT group
Number of subjects: 243
Study: 37133829

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic BP target < 120 mm Hg)
Number of subjects: 7874

Group type: COMPARATOR
Intervention: Standard treatment (systolic BP target < 140 mm Hg)
Number of subjects: 7874

Group type: COMPARATOR
Intervention: Negative control (right bundle-branch block)
Number of subjects: 7874
Study: 37133856

Group type: EXPERIMENTAL
Intervention: Roflumilast foam, 0.3%
Number of subjects: 226

Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 226
Study: 37133909

Group type: EXPERIMENTAL
Intervention: PIMPmyHospital app
Number of subjects: 0
Study: 37133926

Group type: EXPERIMENTAL
Intervention: BCI-based app-delivered mindfulness meditation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 84
Study: 37134108

Group type: EXPERIMENTAL
Intervention: Avasimibe (ACAT inhibitor)
Number of subjects: 0
Study: 37134130

Group type: EXPERIMENTAL
Intervention: Fixed-schedule rituximab infusion (500 mg)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Tailored-infusion regimen of rituximab
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Low rituximab plasma concentration at 3 months (CM3 <4 μg/ml)
Number of subjects: 135
Study: 37134230

Group type: EXPERIMENTAL
Intervention: TPD (new powder dressing)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional compression dressing therapy
Number of subjects: 60
Study: 37134294

Group type: COMPARATOR
Intervention: Flutamide
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Flutamide+PROSTVAC
Number of subjects: 64
Study: 37137248

Group type: EXPERIMENTAL
Intervention: Event-Related Potential (ERP) methodology
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Resting state functional magnetic resonance imaging (rsf/MRI) methodology
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neuropsychological testing (N-P)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Self-report Quality-Of-Life methodologies
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy control (HC) participants
Number of subjects: 40
Study: 37137304

Group type: EXPERIMENTAL
Intervention: ChemoID assay-guided chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician-chosen chemotherapy
Number of subjects: 0
Study: 37137378

Group type: EXPERIMENTAL
Intervention: ICD-10 code I61
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: ICD-10 code I63.x
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: ICD-10 codes I60.1-7, I61, I62.9, I63
Number of subjects: 304
Study: 37137388

Group type: EXPERIMENTAL
Intervention: TetraGraph
Number of subjects: 100

Group type: COMPARATOR
Intervention: TOFscan
Number of subjects: 100
Study: 37137444

Group type: EXPERIMENTAL
Intervention: 22-gene Decipher genomic classifier (GC)
Number of subjects: 215

Group type: COMPARATOR
Intervention: 22-gene Decipher genomic classifier (GC) low-risk patients
Number of subjects: 215

Group type: COMPARATOR
Intervention: 22-gene Decipher genomic classifier (GC) lower scores
Number of subjects: 215
Study: 37137527

Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous semaglutide
Number of subjects: 1278

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1278
Study: 37137553

Group type: EXPERIMENTAL
Intervention: BCMA CAR-T therapy
Number of subjects: 1
Study: 37137560

Group type: COMPARATOR
Intervention: Nurse practitioner roles implemented in three departments of a Belgian university hospital.
Number of subjects: 0
Study: 37137586

Group type: EXPERIMENTAL
Intervention: PASCAL transcatheter valve repair system
Number of subjects: 65
Study: 37137588

Group type: EXPERIMENTAL
Intervention: Lipoprotein(a) (Lp[a])
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: OxPL-apoB
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: OxPL-apo(a)
Number of subjects: 1098
Study: 37137590

Group type: EXPERIMENTAL
Intervention: Coronary-related hospitalizations among women
Number of subjects: 2979

Group type: EXPERIMENTAL
Intervention: Noncardiac hospitalizations among women
Number of subjects: 2979
Study: 37137617

Group type: EXPERIMENTAL
Intervention: Adequate vitamin B
Number of subjects: 977

Group type: COMPARATOR
Intervention: RBC folate deficiency (<305 nmol/L) and insufficiency (<748 nmol/L)
Number of subjects: 977
Study: 37137660

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 0
Study: 37137672

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 37137673

Group type: EXPERIMENTAL
Intervention: Quadriceps-focused exercise (QE)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hip-focused exercise (HE)
Number of subjects: 200
Study: 37137675

Group type: EXPERIMENTAL
Intervention: Trientine for 52 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo for 52 weeks
Number of subjects: 0
Study: 37137684

Group type: EXPERIMENTAL
Intervention: PPT diet
Number of subjects: 200

Group type: COMPARATOR
Intervention: MED diet
Number of subjects: 200
Study: 37138195

Group type: EXPERIMENTAL
Intervention: Highly myopic eyes (AL ≥ 26 mm)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Highly myopic eyes (AL ≥ 28 mm)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Follow-up duration
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Axial length (AL)
Number of subjects: 673

Group type: COMPARATOR
Intervention: Control eyes (AL < 26 mm)
Number of subjects: 673
Study: 37138202

Group type: EXPERIMENTAL
Intervention: Sub-symptom threshold aerobic exercise (SSTAE) for 12 weeks in addition to ordinary rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordinary rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SSTAE
Number of subjects: 0
Study: 37138228

Group type: EXPERIMENTAL
Intervention: Systemic organ communication in STEMI (SYSTEMI) study intervention
Number of subjects: 150
Study: 37138243

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LS)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Open operation (OP)
Number of subjects: 645
Study: 37138268

Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative (QIC) intervention including learning sessions, action periods, and workshops informed by joint learning, co-design, and evidence-based practices.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative (QIC) intervention
Number of subjects: 0
Study: 37138460

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine trial participation
Number of subjects: 349
Study: 37138473

Group type: EXPERIMENTAL
Intervention: Pegloticase (8 mg intravenous every 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study: 37138742

Group type: EXPERIMENTAL
Intervention: New Echinacea formulation
Number of subjects: 246

Group type: COMPARATOR
Intervention: Conventional Echinacea formulation
Number of subjects: 246